Coeptis Therapeutics (NASDAQ:ZSQR) Trading 14% Higher – What’s Next?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) shares traded up 14% during trading on Monday . The company traded as high as $10.68 and last traded at $10.61. 168,595 shares were traded during trading, an increase of 88% from the average session volume of 89,587 shares. The stock had previously closed at $9.31.

Coeptis Therapeutics Price Performance

The stock has a market cap of $542.08 million, a price-to-earnings ratio of -4.18 and a beta of -0.09. The company has a 50 day simple moving average of $11.97 and a 200-day simple moving average of $13.29. The company has a quick ratio of 3.25, a current ratio of 3.25 and a debt-to-equity ratio of 0.01.

Coeptis Therapeutics (NASDAQ:ZSQR) last posted its earnings results on Thursday, May 14th. The company reported ($0.65) EPS for the quarter. The company had revenue of $0.11 million for the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%.

Hedge Funds Weigh In On Coeptis Therapeutics

Several institutional investors have recently made changes to their positions in ZSQR. Yorkville Advisors Global LP bought a new position in shares of Coeptis Therapeutics during the third quarter valued at approximately $140,000. Geode Capital Management LLC grew its holdings in shares of Coeptis Therapeutics by 12.6% during the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after purchasing an additional 4,721 shares during the last quarter. Steward Partners Investment Advisory LLC grew its holdings in shares of Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after purchasing an additional 2,500 shares during the last quarter. State Street Corp grew its holdings in Coeptis Therapeutics by 35.0% in the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after buying an additional 6,962 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in Coeptis Therapeutics in the 4th quarter worth approximately $259,000. 13.88% of the stock is owned by institutional investors.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.